News
-
-
PRESS RELEASE
There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate
NanoViricides, Inc. announces advancing lead candidate NV-387 into Phase II clinical development for MPox. Protocol development and site addition underway in the DRC. Focus on antiviral drug against MPox/Smallpox -
-
PRESS RELEASE
Market analysis by Kirchhoff and CMS: Every fourth company in the DAX160 voluntarily publishes preliminary figures
Market analysis by Kirchhoff Consult and CMS reveals that 1 in 4 DAX160 companies voluntarily release preliminary financial figures, posing legal risks and transparency challenges. Recommendations for communication and legal protection provided -
-
-
PRESS RELEASE
comdirect relies on tick Trading Software AG for ProTrader: New generation of trading software for active retail traders
tick Trading Software AG collaborates with comdirect to launch ProTrader, a new trading software for active retail traders, offering user-friendly and reliable features -
PRESS RELEASE
Mallia Innovations: Mallia Appoints Jens Holstein, Dr. Alexandra Ogilvie, and Dr. Ulrich Dauer to its Advisory Board
Mallia Innovations appoints Jens Holstein, Dr. Alexandra Ogilvie, and Dr. Ulrich Dauer to its Advisory Board, strengthening expertise in biopharmaceutical and dermatology sectors -
-
PRESS RELEASE
Proenkephalin A 119–159 (penKid) Leads the Way in Predicting Graft Outcomes for Kidney Transplant Recipients
Research study reveals Proenkephalin A 119-159 (penKid) as a superior biomarker for predicting kidney transplant outcomes, offering early detection and precise assessment of graft function trajectories